Fatal status epilepticus associated with olanzapine therapy

被引:40
作者
Wyderski, RJ [1 ]
Starrett, WG [1 ]
Abou-Saif, A [1 ]
机构
[1] Wright State Univ, Sch Med, Dept Internal Med, Dayton, OH USA
关键词
status epilepticus; olanzapine;
D O I
10.1345/aph.18399
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of fatal status epilepticus in a patient using olanzapine with no known underlying cause or predisposing factor for seizure. CASE SUMMARY: A 41-year-old white woman developed witnessed seizures at home that progressed to status epilepticus, She subsequently died from secondary rhabdomyolysis and disseminated intravascular coagulation. She had been taking olanzapine for five months prior to the event. No other toxic, metabolic, or anatomic abnormalities were identified pre- or postmortem to explain the seizures. Her seizures were a probable adverse drug reaction based on the Naranjo scale. DISCUSSION: This is the first case of fatal status epilepticus described that has been associated with the use of olanzapine. The pharmacodynamics of olanzapine are similar to those of clozapine, which has been described to induce seizures in 1-4% of patients. It is possible that this patient may have suffered seizures due to a similar effect. Alternate explanations include neuroleptic malignant syndrome and alcohol or benzodiazepine withdrawal seizures, although her clinical history does not suggest these etiologies. CONCLUSIONS: Although olanzapine has infrequently been associated with seizures in premarketing studies, its potential to induce them exists. Postmarketing surveillance should continue to determine how significant this effect may be.
引用
收藏
页码:787 / 789
页数:3
相关论文
共 12 条
[1]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[2]  
Bithell Thomas C., 1993, P1473
[3]  
Casey DE, 1996, J CLIN PSYCHIAT, V57, P40
[4]  
DEVINSKY O, 1994, J CLIN PSYCHIAT, V55, P153
[5]  
Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12
[6]   Disseminated intravascular coagulation and status epilepticus [J].
Felcher, A ;
Commichau, C ;
Cao, Q ;
Brown, MJ ;
Torres, A ;
Francis, CW .
NEUROLOGY, 1998, 51 (02) :629-631
[7]   Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses [J].
Fulton, B ;
Goa, KL .
DRUGS, 1997, 53 (02) :281-298
[8]   Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique [J].
Hasan, S ;
Buckley, P .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (08) :1113-1116
[9]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[10]   In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A [J].
Ring, BJ ;
Binkley, SN ;
Vandenbranden, M ;
Wrighton, SA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (03) :181-186